Amphetamine Stimulant denied as not medically necessary by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for amphetamine stimulant are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare Denies Amphetamine Stimulants for Medical Necessity — and How to Appeal

Medical-necessity denials for amphetamine stimulants typically occur when UnitedHealthcare's reviewer concludes that the submitted documentation does not sufficiently establish that the medication is required for the patient's diagnosed condition, or that the clinical record does not meet the specific criteria in UHC's coverage policy. This can happen when prior-authorization paperwork is sparse, when a diagnosis has not been formally confirmed by a qualifying evaluation, or when UHC's internal policy requires a particular documentation standard (such as functional-impairment scoring or structured diagnostic criteria) that was not provided.

These denials are among the most commonly reversed on appeal, because the clinical evidence almost always exists in the treating provider's records — it simply was not included in the original authorization request.

## Your Federal Appeal Rights

• Internal appeal (ERISA §503): You are entitled to a full-and-fair review. The plan must disclose every criterion it applied, every document it relied on, and must allow you to submit additional evidence. A denial based on incomplete documentation is not final.
• External review (ACA §2719): If the internal appeal is denied, request independent external review within the window stated in your denial letter (typically approximately 180 days from the final internal denial). The IRO reviewer applies recognized medical standards independently of UHC's internal policies.
• Expedited review: If you are experiencing significant functional impairment or safety concerns from untreated symptoms, request expedited review. Most plans must respond within 72 hours.

## Documentation to Gather

1. Formal diagnosis confirmation — Documentation of a comprehensive evaluation meeting recognized diagnostic criteria for ADHD (or the applicable diagnosis), including the evaluating clinician's name, date, and findings. 2. Functional-impairment evidence — Chart notes, rating scales, or clinical narrative describing how the untreated condition affects daily functioning, occupational performance, academic performance, or safety. 3. Prior treatment history — A chronological record of all prior treatments attempted, with dates, outcomes, and reasons for discontinuation or inadequacy. 4. Prescriber medical-necessity letter — A letter from the treating physician explaining the clinical basis for this specific medication, why it is necessary for this patient, and how it aligns with the FDA-approved prescribing information and applicable clinical guideline organizations. 5. Response to prior therapy (if applicable) — If the patient has previously responded to this medication, include that documentation; if this is a new start, include the clinical rationale.

## Criteria-Mapping Strategy

Obtain UHC's clinical coverage policy for amphetamine stimulants. List every criterion. For each one, provide the specific chart finding, date, and clinician who documented it. Do not summarize — match each requirement with a precise record citation. This structure forces the reviewer to address every criterion individually and makes it harder to deny on vague grounds.